Body Weight Variability and Risk of Cardiovascular Outcomes and Death in the Context of Weight Loss Intervention Among Patients With Type 2 Diabetes.

Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE

Original Publication: Chicago, IL : American Medical Association, [2018]-

Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/epidemiology; Body Weight/*physiology; Adiposity/physiology ; Aged ; Cardiovascular Diseases/complications ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/mortality ; Female ; Humans ; Life Style ; Male ; Middle Aged ; Prospective Studies ; United States ; Waist Circumference/physiology

Importance: Body weight fluctuation is associated with greater risks of adverse health outcomes. Whether intensive weight loss interventions affect the association of variability in adiposity measures with adverse health outcomes in individuals with type 2 diabetes has not been studied previously.
Objective: To evaluate the associations of long-term variability in adiposity indices with cardiovascular disease (CVD) outcomes and whether these associations are affected by an intensive lifestyle intervention among adults with type 2 diabetes.
Design, Setting, and Participants: This prospective cohort study included participants in the Action for Health in Diabetes (Look AHEAD) trial without CVD at baseline (August 2001 to April 2004). The Look AHEAD study included 16 centers in the United States. Data analysis was performed from December 2020 to June 2021.
Exposures: Variability of body mass index (BMI) and waist circumference (WC) across 4 annual visits, assessed using the coefficient of variation (CV), variability independent of the mean (VIM), and standard deviation (SD).
Main Outcomes and Measures: Main outcomes were (1) all-cause mortality, (2) cardiovascular deaths (deaths from myocardial infarction [MI] or stroke), and (3) CVD events (MI, stroke, and/or death from cardiovascular causes).
Results: Among 3604 study participants (mean [SD] age, 58.4 [6.6] years; 2240 [62.3%] women; 1364 [37.7%] Black participants; 2404 [66%] White participants), there were 216 CVD events, 33 CVD deaths, and 166 deaths over a median of 6.7 years. In the control group, the hazard ratios (HRs) for the highest quartile (quartile 4) compared with the lowest quartile (quartile 1) of CV of BMI were 4.06 (95% CI, 2.17-7.57), 15.28 (95% CI, 2.89-80.90), and 2.16 (95% CI, 1.21-3.87) for all-cause mortality, CVD mortality, and cardiovascular events, respectively. In the intervention group, the corresponding HRs were 0.99 (95% CI, 0.45-2.16), 1.14 (95% CI, 0.12-10.53), and 0.77 (95% CI, 0.40-1.49) for quartile 4 vs quartile 1. Regarding WC, in the control group, HRs for quartile 4 vs quartile 1 were 1.84 (95% CI, 1.01-3.35), 6.46 (95% CI, 1.16-36.01), and 1.28 (95% CI, 0.72-2.29). In the intervention group, HRs were 1.23 (95% CI, 0.61-2.46), 0.55 (95% CI, 0.15-2.11), and 0.70 (95% CI, 0.39-1.25) for quartile 4 vs quartile 1.
Conclusions and Relevance: In this cohort study of individuals with type 2 diabetes, higher variability of adiposity indices was associated with significantly increased risk of CVD outcomes and death in the control group but not in the intensive lifestyle intervention group.

Control Clin Trials. 2003 Oct;24(5):610-28. (PMID: 14500058)
Circulation. 2012 Sep 4;126(10):1301-13. (PMID: 22949540)
Sports Med. 2018 Feb;48(2):269-288. (PMID: 29127602)
J Am Heart Assoc. 2019 Apr 2;8(7):e010793. (PMID: 31025893)
Circ Cardiovasc Qual Outcomes. 2018 Nov;11(11):e004724. (PMID: 30571333)
Obes Rev. 2015 Feb;16 Suppl 1:7-18. (PMID: 25614199)
Circ J. 2005 Jan;69(1):13-8. (PMID: 15635195)
Diabetes Care. 2011 Jun;34(6):1424-30. (PMID: 21602431)
J Clin Hypertens (Greenwich). 2012 Nov;14(11):744-50. (PMID: 23126345)
Diabetes Care. 2020 Jan;43(Suppl 1):S89-S97. (PMID: 31862751)
N Engl J Med. 2017 Jul 6;377(1):95-6. (PMID: 28679098)
Curr Opin Clin Nutr Metab Care. 2015 Nov;18(6):535-51. (PMID: 26335310)
N Engl J Med. 1991 Jun 27;324(26):1839-44. (PMID: 2041550)
Diabetes Metab Res Rev. 2008 Nov-Dec;24(8):624-8. (PMID: 18802932)
JAMA. 2015 Sep 8;314(10):1021-9. (PMID: 26348752)
Diabetes Care. 2019 Mar;42(3):486-493. (PMID: 30659073)
Clin Nutr. 2011 Dec;30(6):718-23. (PMID: 21764186)
Med Sci Sports Exerc. 2008 Nov;40(11):1863-72. (PMID: 18845966)
JAMA. 2016 Jun 7;315(21):2284-91. (PMID: 27272580)
Diabetes. 2013 Sep;62(9):3180-8. (PMID: 23733197)
Ann Intern Med. 2007 Oct 16;147(8):573-7. (PMID: 17938396)
Am J Cardiol. 2019 Feb 15;123(4):576-581. (PMID: 30553512)
Int J Obes. 1990 Apr;14(4):373-83. (PMID: 2361814)
J Am Heart Assoc. 2019 Sep 17;8(18):e013471. (PMID: 31480883)
N Engl J Med. 2013 Jul 11;369(2):145-54. (PMID: 23796131)
Ann Intern Med. 2009 May 5;150(9):604-12. (PMID: 19414839)
Int J Obes. 1990 Apr;14(4):303-10. (PMID: 2361807)
Int J Obes Relat Metab Disord. 2003 Sep;27(9):1059-65. (PMID: 12917711)
Diab Vasc Dis Res. 2006 Dec;3(3):202-15. (PMID: 17160917)
Diabetes Care. 2020 Sep;43(9):2234-2241. (PMID: 32641375)

K23 HL153774 United States HL NHLBI NIH HHS

Date Created: 20220218 Date Completed: 20220308 Latest Revision: 20230408

20231215

PMC8857684

10.1001/jamanetworkopen.2022.0055

35179583